Artia Global Partners LP lessened its stake in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) by 83.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 90,279 shares of the biotechnology company's stock after selling 442,600 shares during the quarter. Viking Therapeutics comprises about 1.3% of Artia Global Partners LP's investment portfolio, making the stock its 17th biggest holding. Artia Global Partners LP owned 0.08% of Viking Therapeutics worth $3,633,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Aquatic Capital Management LLC bought a new position in shares of Viking Therapeutics during the 4th quarter valued at about $8,416,000. Oxford Asset Management LLP acquired a new stake in Viking Therapeutics during the fourth quarter valued at approximately $299,000. Gilder Gagnon Howe & Co. LLC bought a new stake in Viking Therapeutics during the fourth quarter worth approximately $671,000. Syon Capital LLC acquired a new position in Viking Therapeutics in the fourth quarter worth approximately $312,000. Finally, J. Safra Sarasin Holding AG bought a new position in shares of Viking Therapeutics in the fourth quarter valued at $552,000. Institutional investors own 76.03% of the company's stock.
Analyst Ratings Changes
A number of equities analysts recently issued reports on the company. HC Wainwright restated a "buy" rating and issued a $102.00 target price on shares of Viking Therapeutics in a report on Thursday. Piper Sandler dropped their price target on Viking Therapeutics from $74.00 to $71.00 and set an "overweight" rating on the stock in a research note on Thursday, February 6th. Morgan Stanley reduced their price objective on shares of Viking Therapeutics from $105.00 to $102.00 and set an "overweight" rating for the company in a research note on Thursday. Raymond James raised their target price on shares of Viking Therapeutics from $122.00 to $125.00 and gave the stock a "strong-buy" rating in a report on Thursday, February 6th. Finally, Scotiabank began coverage on shares of Viking Therapeutics in a report on Thursday, February 13th. They set a "sector outperform" rating and a $102.00 price target on the stock. One analyst has rated the stock with a sell rating, two have given a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $89.50.
Check Out Our Latest Stock Analysis on VKTX
Viking Therapeutics Trading Down 2.6 %
NASDAQ VKTX opened at $24.99 on Friday. Viking Therapeutics, Inc. has a 1-year low of $18.92 and a 1-year high of $81.86. The firm's fifty day simple moving average is $26.47 and its 200-day simple moving average is $40.49. The company has a market capitalization of $2.81 billion, a PE ratio of -24.99 and a beta of 0.84.
Viking Therapeutics (NASDAQ:VKTX - Get Free Report) last posted its quarterly earnings results on Wednesday, April 23rd. The biotechnology company reported ($0.41) earnings per share for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.07). During the same period in the prior year, the firm earned ($0.26) earnings per share. As a group, analysts predict that Viking Therapeutics, Inc. will post -1.56 EPS for the current year.
Insider Buying and Selling at Viking Therapeutics
In related news, Director Sarah Kathryn Rouan purchased 1,240 shares of the firm's stock in a transaction dated Monday, March 31st. The stock was bought at an average price of $24.15 per share, for a total transaction of $29,946.00. Following the purchase, the director now owns 1,240 shares in the company, valued at $29,946. The trade was a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 4.10% of the company's stock.
Viking Therapeutics Profile
(
Free Report)
Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Viking Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Viking Therapeutics wasn't on the list.
While Viking Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
